Dr. Nakazawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1650 Orleans St
CRB1-Room 186
Baltimore, MD 21287Phone+1 410-955-8893
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2022- Johns Hopkins UniversityResidency, Internal Medicine, 2019 - 2022
University of Kentucky College of MedicineClass of 2019
Certifications & Licensure
MD State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 1 citationsImmune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.Chester J Kao, Soren Charmsaz, Stephanie L Alden, Madelena Brancati, Howard L Li
The Journal of Clinical Investigation. 2024-08-29 - Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith
Cancer Research Communications. 2024-08-01 - Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski
Cancer Research Communications. 2024-03-14
Press Mentions
Neoadjuvant Immunotherapy for Liver Cancer: Shrinking Tumors, Growing ResponsesOctober 18th, 2024- Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver CancerAugust 23rd, 2024
- Immunotherapy Prior to Surgery May Improve Outcomes for High-Risk Liver Cancer PatientsAugust 21st, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
